Gamitrinib Therapy for Prostate Cancer
Author Information
Author(s): Kang B H, Tavecchio M, Goel H L, Hsieh C-C, Garlick D S, Raskett C M, Lian J B, Stein G S, Languino L R, Altieri D C
Primary Institution: Wistar Institute Cancer Center
Hypothesis
Can Gamitrinib effectively inhibit localized and metastatic prostate cancer growth in a genetic mouse model?
Conclusion
Gamitrinib shows pre-clinical activity and favorable tolerability in a genetic model of localized and metastatic prostate cancer.
Supporting Evidence
- Gamitrinib treatment inhibited localized prostate tumors and metastatic cancer in TRAMP mice.
- Long-term treatment did not cause significant weight loss or organ toxicity.
- Gamitrinib triggered mitochondrial dysfunction in cancer cells.
Takeaway
Gamitrinib is a new treatment that helps stop prostate cancer from growing in mice without making them sick.
Methodology
The study tested Gamitrinib in TRAMP mice for its effects on prostate cancer using imaging and histological analysis.
Limitations
The study is based on a mouse model, which may not fully replicate human prostate cancer.
Participant Demographics
TRAMP mice, a genetic model of prostate cancer.
Statistical Information
P-Value
0.0038
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website